New combo therapy hopes to shrink Hard-to-Treat cancers
NCT ID NCT06771622
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called HCB101 given together with other cancer treatments for people with advanced solid tumors that have not responded well to prior therapy. About 500 adults will take part to find the safest dose and see if the combination can shrink tumors. The goal is to control the disease, not to cure it, as ongoing treatment is expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?